Sign In
Buy MRK
$119.05
-1.73 (-1.43%)
At Close: Jun 12, 2026
Keystone Financial Loads Up on This Free Cash Flow ETF
03:52pm, Tuesday, 24'th Feb 2026
The ETF tracks a rules-based index of 50 U.S. large- and mid-cap companies with strong free cash flow profiles.
Amazon, Merck, PG&E And More On CNBC's 'Final Trades'
08:26am, Tuesday, 24'th Feb 2026
Amazon invests $12 billion in data centers in Louisiana, Merck and Co., Inc. receives positive coverage, and Horizon Kinetics Inflation Beneficiaries ETF shows slight growth.
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
06:45am, Tuesday, 24'th Feb 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the TD Cowen 46th Annual Health Care Conference.
Market Today: Tariffs, AI Jitters; LLY, MRK, WBD in Focus
05:39pm, Monday, 23'rd Feb 2026
Guru Stock PicksBernard Horn has made the following transactions:Reduce in XSWX: BARN by 39.89%Sold out in CGAdd in TSN by 18.45%New position in HKSE:01299Stock
Merck creates separate oncology arm ahead of Keytruda patent loss
09:11am, Monday, 23'rd Feb 2026
Merck said on Monday that it will split its human-health operations into two separate divisions, a move designed to sharpen focus across its portfolio and ensure smoother launches of new medicines. Th
Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs
08:27am, Monday, 23'rd Feb 2026
Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a reorg
Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.
07:38am, Monday, 23'rd Feb 2026
The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
06:45am, Monday, 23'rd Feb 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Evolves Human Health Operating Structure to Support Portfolio Execution.
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports
06:22am, Monday, 23'rd Feb 2026
Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.
Merck & Co., Inc. (NYSE:MRK) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
04:06am, Monday, 23'rd Feb 2026
Shares of Merck and Co., Inc. (NYSE: MRK - Get Free Report) have been given an average rating of "Moderate Buy" by the seventeen analysts that are covering the company, MarketBeat Ratings reports. One
Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades
03:45pm, Sunday, 22'nd Feb 2026
The pharmaceutical giant is finding ways to navigate despite headwinds. This has helped the shares outperform the market over the past year.
Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement?
11:01am, Sunday, 22'nd Feb 2026
Merck is one of the world's largest drug companies. Although it isn't a player in the GLP-1 space, it has a well-supported dividend and a proven track record of dividend growth.
Merck: Why Investors Should Remain Bullish Despite Patent Risks
08:00am, Sunday, 22'nd Feb 2026
Merck started 2026 on a high note. On February 13, its stock reached a 52-week high of $123.3. One of the key reasons Merck is once again becoming a Wall Street favorite is the 6.8% year-over-year inc
Pharma Stock's Rally Stalling Out at Technical Resistance
02:14pm, Friday, 20'th Feb 2026
Shares of drug-maker Merck (MRK) stalled on the charts at the early 2024 pivot breakdown level. The equity is also losing steam around resistance at the $120 zone, with the final decent call open inte
